跳至主要内容
临床试验/NCT03252340
NCT03252340已完成不适用

Observational Study to Evaluate the Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

EHL Bio Co., Ltd.1 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2017年9月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
11
试验地点
1
主要终点
Tumor formation

研究概览

简要总结

This study aims to evaluate safety in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of ADSTEM Inj. Since this is an observational study of patients participated in Phase 1 clinical trials, no drug is administered in this study.

详细描述

Participants will be followed-up for adverse events on each visit. Visits will be on 6, 12, 18, 24, 30, 36, 48, 60months after treatment of ADSTEM Inj.

Time perspective is both retrospective and prospective.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Other

入排标准

年龄范围
19 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who participated in Phase I clinical trials
  • Patients who voluntarily agreed to participate in the study

排除标准

  • Patients who can not follow-up from the end of the phase 1 clinical trial to the end of the study

研究组 & 干预措施

Drug: ADSTEM Inj.

Participants in Phase I clinical trials treated with ADSTEM Inj.

干预措施: ADSTEM Inj. (Drug)

结局指标

主要结局

Tumor formation

时间窗: 60months after treatment of ADSTEM Inj.

The number of subjects with treatment-related tumor formation

次要结局

  • Adverse events(60months after treatment of ADSTEM Inj.)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验